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MicroRNAs (miRNAs) are small noncoding RNAs that
regulate vast networks of genes that share miRNA
target sequences. To examine the physiologic ef-
fects of an individual miRNA-mRNA interaction in
vivo, we generated mice that carry a mutation in the
putative microRNA-155 (miR-155) binding site in the
30-untranslated region of activation-induced cytidine
deaminase (AID), designated Aicda155 mice. AID is
required for immunoglobulin gene diversification
in B lymphocytes, but it also promotes chromo-
somal translocations. Aicda155 caused an increase
in steady-state Aicda mRNA and protein amounts
by increasing the half-life of the mRNA, resulting in
a high degree of Myc-Igh translocations. A similar
but more pronounced translocation phenotype was
also found in miR-155-deficient mice. Our experi-
ments indicate that miR-155 can act as a tumor
suppressor by reducing potentially oncogenic trans-
locations generated by AID.
INTRODUCTION
Antibody genes are assembled in developing B cells by RAG1-
RAG2 recombinase-mediated site-specific recombination of
immunoglobulin (Ig) variable (V), diversity (D), and joining (J)
gene segments. Although V(D)J recombination produces a
diverse repertoire of IgM antibodies, high-affinity IgG antibody
responses require further Ig diversification by somatic hypermu-
tation (SHM) and class-switch recombination (CSR) in antigen-
activated B cells (Klein and Dalla-Favera, 2008; Meffre et al.,
2000; Rajewsky, 1996). These reactions are both initiated by
activation-induced cytidine deaminase (AID), which deaminates
cytosine residues and introduces U:G mismatches in DNA (Di
Noia and Neuberger, 2007; Muramatsu et al., 2007). AID activity
is primarily restricted to Ig genes but can also produce off-target
lesions in non-Ig sites such as oncogenes (Liu et al., 2008), and
the double-strand breaks it creates can be substrates for trans-630 Immunity 28, 630–638, May 2008 ª2008 Elsevier Inc.location (Dorsett et al., 2007; Ramiro et al., 2004). Therefore,
the regulation of this enzyme is essential to maintain genomic
integrity.
MicroRNAs (miRNAs) are a class of 20–23 nt noncoding
RNAs produced from genes encoding RNAs with a hairpin sec-
ondary structure (Bartel, 2004; Filipowicz et al., 2008; Meister
and Tuschl, 2004). The hairpin RNAs are processed to produce
mature single-stranded small RNAs (the microRNA) that are
then incorporated into protein complexes termed, miRNPs, that
contain one of several different Argonaute proteins (Filipowicz
et al., 2008; Meister and Tuschl, 2004). miRNA binding to comple-
mentary sequences, usually located in the 30-untranslated re-
gions (30 UTRs) of messenger RNAs (mRNAs), can regulate ex-
pression of large groups of genes by a variety of mechanisms
including cleavage, degradation, cell-cycle control, translational
inhibition, and mRNA transport (Bartel, 2004; Filipowicz et al.,
2008; Leung and Sharp, 2007; Meister and Tuschl, 2004).
miR-155 is an oncogenic miRNA product of theMIRN155 gene
in humans orBic in mice and is deregulated in a number of differ-
ent cancers, most of which are of B cell origin (Costinean et al.,
2006; Eis et al., 2005; Fulci et al., 2007; Gironella et al., 2007; Iorio
et al., 2005; Jay et al., 2007; Kluiver et al., 2005, 2006, 2007;
Lagos-Quintana et al., 2002; Landgraf et al., 2007; Lawrie
et al., 2007; Lee et al., 2007; Marton et al., 2008; Nikiforova
et al., 2008; Roldo et al., 2006; Tam, 2001; Volinia et al., 2006).
Overexpression of miR-155 in transgenic mice leads to preleuke-
mic pre-B cell proliferation in bone marrow and spleen, followed
by high-grade B cell neoplasms (Costinean et al., 2006).
Conversely, the mature form of miR-155 is absent in primary
cases of Burkitt’s lymphoma (Kluiver et al., 2006, 2007; Landgraf
et al., 2007). Although the precise role of miR-155 in promoting
lymphomagenesis has not been determined, this miRNA is an
important immune modulator whose expression is induced
along with AID in activated leukocytes and germinal center
B cells (Haasch et al., 2002; Taganov et al., 2006; Tam, 2001;
Thai et al., 2007; van den Berg et al., 2003). miR-155 deficiency
in mice leads to the deregulated expression of hundreds of
mRNAs, some of which are direct targets of miR-155, resulting
in abnormalities in the germinal center reaction and antibody re-
sponses in vivo (Rodriguez et al., 2007; Thai et al., 2007; Vigorito
et al., 2007).
Immunity
miR-155 Suppresses AID-Mediated TranslocationsAicda encodes AID and contains a single miR-155 binding site
in its 30 UTR (John et al., 2004; Lewis et al., 2005). It is among the
genes deregulated in miR-155-deficient B cells, where its ex-
pression is increased 1.6-fold as measured by gene array (Vigor-
ito et al., 2007). However, this small change in mRNA expression
was not confirmed by a direct measurement, and whether this is
a direct or indirect effect of miR-155 deletion has not been
determined. With a few exceptions, miRNA control in living
organisms has been studied by overexpression and deletion
experiments (Choi et al., 2007; Mayr et al., 2007). These ap-
proaches result in simultaneous effects on many genes that
share miRNA target sequences, complicating interpretation
because indirect regulators are themselves miRNA targets.
To determine whether miR-155 regulates AID expression
directly, and to investigate the potential significance of that reg-
ulation in Burkitt’s lymphoma-associated Myc-Igh translocation,
we produced a mouse strain that carries a mutation in the puta-
tive miR-155 target site in the 30 UTR of the gene encoding AID
(Aicda155 mice) and compared them to miR-155-deficient mice.
RESULTS
Aicda155 Mice
Like Aicda, miR-155 appears to have emerged in evolution in
bony fish and the 30 UTR of Aicda contains a candidate miR-
155 binding site that is conserved between fish and humans,
suggesting that the two may have coevolved (Figures S1A–
S1C available online) (Barreto et al., 2005; Conticello et al.,
2005, 2007; Lewis et al., 2003, 2005; Wakae et al., 2006). To
examine the effects of miR-155 on AID expression directly, we
replaced the conserved miR-155 target sequence (seed-match
nucleotides 1–8) in the 30 UTR of Aicda with a G- and C-rich nu-
cleotide sequence that does not match the seed sequence
of any known miRNAs (Figures S1A and S2). The mutation
was confirmed by sequencing of the Aicda mRNA from the mu-
tant mice (not shown). Aicda155/+ mice were bred to C57Bl/6
Aicda/ mice to produce Aicda155/ mice that were born at
normal frequencies (not shown). When compared to wild-type
or Aicda+/ controls by flow cytometry, Aicda155/ showed nor-
mal B cell development in the bone marrow and normal numbers
of peripheral B cells in spleen (Figure S3A). In addition, the
amount of serum-immunoglobulin isotypes was normal as
measured by enzyme-linked immunoassays (Figure S3B).
Aicda155 and miR-155-Deficient Mice Express
Higher Amounts of AID Protein
To determine whether the Aicda155 mutation altered AID protein
expression, we stimulated B cells with lipopolysacharide (LPS)
and interleukin 4 (IL-4) in vitro to induce AID and miR-155, and
we measured AID protein expression over 4 days (Figures 1A
and 1B). In control B cells, AID protein expression was initially
detected 2 days after stimulation and increased on days 3 and
4 in culture (Figures 1A and 1B, and data not shown). Aicda155/
showed a similar expression pattern, but in all cases the amounts
were 2- to 3-fold higher than in Aicda+/ controls, as determined
by immunoblot (Figures 1A and 1B). Similar effects were also
found in miR-155-deficient B cells (Figures 1C and 1D). We
conclude that miR-155 regulates the amount of AID protein in
stimulated B cells.miR-155 Destabilizes Aicda mRNA
Consistent with elevated amounts of AID protein, the corre-
sponding mRNA was elevated in Aicda155/ when compared to
Aicda+/ controls beginning 2 days after stimulation with LPS
and IL-4 (Figure 1E). Similar results were found with miR-155-
deficient B cells, which show a 2.5-fold increase in Aicda
mRNA after 4 days (Figure 1F). Increased Aicda mRNA expres-
sion suggests that miR-155 regulates the expression of this
gene by altering messenger stability. To determine whether
miR-155 regulates Aicda mRNA stability, we stimulated B cells
with LPS and IL-4, blocked transcription with Actinomycin-D,
and measured the decay of Aicda mRNA (Figures 1G and 1H).
We found that the half-life of Aicda transcripts was increased
from 1.05 hr in control to 1.94 hr in the mutant as determined
by linear regression analysis of two mice assayed in triplicate,
indicating that miR-155 regulates the level of Aicda mRNA by
increasing its turnover (Figures 1G and 1H).
Class Switching in Aicda155 andmiR-155-Deficient Mice
To examine the effects of Aicda155 on class-switch recombina-
tion, we labeled B cells with 5-(6)-carboxyfluorescein diacetate
succinimidyl diester (CFSE), a reporter dye for cell division, and
stimulated them with LPS and IL-4. Cell-surface IgG1 expression
was monitored by flow cytometry over a time course of 4 days in
culture. Although cell division was normal, class switching was
enhanced in Aicda155/ when compared to Aicda+/ B cells and
was similar to Aicda+/+ controls (Figure 2A). A similar increase
in switching was seen in Aicda155/155 when compared to
Aicda+/+ (Figure 2B). This effect was most pronounced early in
the culture period, when the number of IgG1-expressing
Aicda+/+ and Aicda155/ cells was nearly double that of Aicda+/
controls (Figure 2A). In contrast, miR-155-deficient B cells
showed a subnormal amount of class switching despite in-
creased AID expression (Figures 1C, 1D, and 2C) (Rodriguez
et al., 2007; Thai et al., 2007; Vigorito et al., 2007)). We conclude
that a 2- to 3-fold increase in AID protein expression leads
to increased class switching in vitro in Aicda155/ but not
miR-155-deficient B cells.
Somatic Hypermutation in Aicda155 Mice
Class switching is associated with AID-induced somatic muta-
tions in the 50 of the switch m (Sm) region (Petersen et al., 2001).
To determine whether Aicda155 also alters the production of
AID-mediated lesions in the Igh switch regions, we measured
the mutations that occur 50 of the switch m region in LPS- and
IL-4-stimulated B cells that had undergone five cell divisions (Pe-
tersen et al., 2001). The small increase in mutations in Aicda155/
B cells 50 of the switch m region was not statistically significant
but corresponded to the increase in class switching at the
same time point (Figure 2D).
AID expression is also necessary to induce somatic hypermu-
tation of immunoglobulin genes (Muramatsu et al., 2000; Revy
et al., 2000; Yoshikawa et al., 2002). To examine the effects of
Aicda155 on somatic mutation in vivo, we immunized mice and
purified germinal-center B cells, which actively mutate their Ig
genes. Like LPS- and IL-4-activated B cells, Aicda155/ germi-
nal-center B cells contained higher amounts of Aicda mRNA
than controls (Figure 3A). Similar to 50 of the switch m region, we
found a statistically insignificant effect on somatic hypermutationImmunity 28, 630–638, May 2008 ª2008 Elsevier Inc. 631
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miR-155 Suppresses AID-Mediated TranslocationsFigure 1. Aicda155 Mice
(A) Immunoblots for AID-protein and tubulin loading controls on extracts of B cells after stimulation with LPS and IL-4 for the indicated times in hours for wild-type
(+/+), Aicda155/, Aicda+/, and Aicda/ mice. The blots show samples prepared from two separate mice for each genotype. Numbers indicate relative amounts
of AID determined by AID/tubulin ratio within each blot measured by densitometry. * indicates the position of AID protein.
(B) Combined data for immunoblot analysis for AID protein from five separate mice. Numbers indicate average relative AID protein expression ofAicda155/ versus
Aicda+/ for each time point.
(C) As in (A) but for matched wild-type (WT) and miR-155-deficient B cells.
(D) As in (B) but for miR-155-deficient versus WT B cells (n = 3 independent mice).
(E) Quantitative PCR analysis for Aicda mRNA from wild-type (WT), Aicda155/, Aicda+/, and Aicda/ B cells after stimulation with LPS and IL-4 for 1, 2, 3, or 4
days. Lines show means from two separate mice, each indicated as a separate symbol (WT = diamond, Aicda155/ = triangle, Aicda+/ = square, and Aicda/ =
circle).
(F) Quantitative PCR analysis for Aicda mRNA from matched wild-type (WT) and miR-155-deficient mice after stimulation with LPS and IL-4 for 1, 2, 3, or 4 days.
Data from three separate mice are shown. WT = diamonds, miR-155/ = triangle.
(G) Quantitative PCR analysis, as in (E), for Aicda mRNA from Aicda155/ or Aicda+/ B cells stimulated with LPS and IL-4 for 3 days, after treatment with
Actinomycin-D for the indicated time. Graph represents triplicate Aicda q-PCR for two mice normalized to GAPDH. Aicda155/ = triangles, Aicda+/ = squares.
(H) Linear regression analysis of the data in (G) shown as ln[RNA] versus time of Actinomycin-D treatment. Aicda155/ = triangles, Aicda+/ = squares.of the noncoding DNA region 30 of IgJH4, which cannot be se-
lected for or against during the germinal-center reaction (Jolly
et al., 1997) (Figures 2D and 3B). Although Bcl6 is also mutated
during the germinal-center reaction (Liu et al., 2008), we found
no increase in mutation at this locus inAicda155/germinal-center
B cells (Figure S4). In conclusion, neither the miR-155 deficiency
(Thai et al., 2007; Vigorito et al., 2007) nor Aicda155 mutation sig-
nificantly increases somatic hypermutation despite elevated AID
expression, and therefore this process is probably regulated by
additional mechanisms.632 Immunity 28, 630–638, May 2008 ª2008 Elsevier Inc.Aicda155 mRNA and Protein Do Not Persist
in Plasmablasts
To determine whether Aicda155 would result in persistence
of Aicda mRNA in plasmablasts, where it is not normally tran-
scribed, we cultured B cells under conditions where they undergo
class switching and develop into CD138 plasmablasts (Horikawa
and Takatsu, 2006) (Figure 2E). As in LPS and IL-4 cultures,
Aicda155 enhanced switching to IgG1 but did not alter plasma-
blast development (Figure 2E). Furthermore, the amount ofAicda
mRNA expressed in plasmablasts was two orders of magnitude
Immunity
miR-155 Suppresses AID-Mediated TranslocationsFigure 2. Class-Switch Recombination by Aicda155 and miR-155-Deficient B Cells
(A) Contour plots show IgG1 expression and CFSE dye dilution by B cells from pairs of wild-type (WT), Aicda155/, Aicda+/, and Aicda/ mice after stimulation
with LPS and IL-4 for 3, 4, or 5 days. Numbers indicate percentage of cells in the gate.
(B) Contour plots show IgG1 expression by B cells from matched pairs of wild-type (WT) and Aicda155/155 mice after stimulation with LPS and IL-4 assayed after
4 days. Numbers indicate percentage of cells in the gate.
(C) As in (A) but for pairs of matched wild-type (WT) and miR-155-deficient mice after stimulation with LPS and IL-4 for 3, 4, or 5 days.
(D) Mutations in the 50 of the Sm region in wild-type (WT), Aicda155/, Aicda+/, and Aicda/ B cells stimulated to undergo CSR in vitro with LPS and IL-4 and
sorted for five cell divisions and IgM expression. Segment sizes in the pie charts are proportional to the number of sequences carrying the number of mutations
indicated in the periphery of the charts. The frequency of mutations per base pair sequenced and the total number of independent sequences analyzed are
indicated underneath and in the center of each chart, respectively. The total number of mutations per number of bases analyzed was as follows: WT, 44/
97,240 bp; Aicda155/, 33/97,240 bp; Aicda+/, 27/95160 bp; and Aicda/, 8/47320 bp.
(E) Contour plots show CD138 expression and CFSE dye dilution by B cells from pairs of wild-type (WT), Aicda155/,Aicda+/, and Aicda/ mice after stimulation
with LPS and IL-4, IL-5, and BAFF for 5 days. Numbers indicate percentage of cells in the gate.
(F) Q-PCR analysis forAicdamRNA from purified CD138 expressing plasmablasts from cultures of wild-type (WT),Aicda155/,Aicda+/, andAicda/ B cells after
stimulation as in (E). Data are relative to B cells stimulated with LPS and IL-4 for 4 days (100%) and represent three separate mice, each indicated as a separate
symbol.less than in B cells stimulated with LPS and IL-4 (Figure 2F). Thus,
Aicda155 increases AID expression in developing B cells, yet it
does not extend AID expression into the plasmablast stage.
Myc-Igh Translocations in Aicda155
and miR-155-Deficient B Cells
In addition to class-switch recombination and somatic mutation,
AID induces potentially oncogenic reciprocal chromosome
translocation between Igh and Myc (Myc-Igh) (Dorsett et al.,
2007; Ramiro et al., 2004, 2006). To examine the effect of
Aicda155 on these translocations, we assayed stimulated B cellsfor aberrant juxtaposition of the chromosomes that carry Myc
and Igh (Potter, 2003; Ramiro et al., 2004) (Figure 4A). In contrast
to the modest effects on somatic mutation, Aicda155/ B cells
showed a 3- to 6-fold increase in translocation frequency
compared to Aicda+/ controls (Figures 4B and 4C, and data
not shown). A similar increase in translocation was seen in
Aicda155/155 compared to wild-type controls (Figure 4D). There-
fore, the mechanisms that restrict somatic mutation in cells
expressing elevated amounts of AID do not limit translocation.
In addition to Aicda, miR-155 is predicted to target numerous
different genes that play a role in the maintenance of genomicImmunity 28, 630–638, May 2008 ª2008 Elsevier Inc. 633
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miR-155 Suppresses AID-Mediated TranslocationsFigure 3. Aicda mRNA Expression and Somatic Hypermutation in Germinal-Center B Cells from Aicda155 Mice
(A) Quantitative PCR analysis forAicdamRNA pooled from germinal-center B cells purified from three immunizedAicda155/ andAicda+/ mice. The relative value
obtained with wild-type B cells stimulated with LPS and IL-4 for 4 days is set to 100. Error bars represent standard deviation.
(B) Mutation analysis of the JH4 intron (Jolly et al., 1997) cloned from purified germinal-center B cells (CD19+, Fas+, GL-7+) obtained from the lymph nodes of
immunized wild-type (WT), Aicda155/, Aicda+/, and Aicda/ mice. Pie charts and statistics are as in Figure 2D. The total number of mutations per number
of bases analyzed was as follows: WT, 107/58,644 bp; Aicda155/, 89/61,359 bp; Aicda+/, 65/62,445 bp; and Aicda/, 5/34,752 bp.integrity (John et al., 2004; Lewis et al., 2005). To determine
whether deregulation of miR-155 might further increase the fre-
quency of AID-dependent Myc-Igh translocations, we assayed
miR-155-deficient B cells. We found a 15-fold enhanced
translocation frequency in the absence of miR-155 compared
to matched controls (Figures 4F and 4G). Thus, miR-155 ex-
pression in activated B cells suppresses Myc-Igh transloca-
tions.
DISCUSSION
AID initiates Ig gene diversification in activated B cells by deam-
inating cytosine to produce U:G mismatches in DNA (Di Noia
and Neuberger, 2007; Muramatsu et al., 2007). These lesions
are processed by ubiquitous DNA-repair pathways and error-
prone polymerases to produce somatic mutations or double-
strand DNA breaks, which are obligate intermediates in immu-
noglobulin class-switch recombination (Di Noia and Neuberger,
2007; Muramatsu et al., 2007). However, in addition to diversi-
fying immune responses, AID can damage the genome by mu-
tating oncogenes and creating substrates for chromosomal
translocations (Dorsett et al., 2007; Klein and Dalla-Favera,
2008; Perez-Duran et al., 2007; Ramiro et al., 2004). Indeed,
AID is essential for translocation between Myc and Igh, and
the frequency of these rare off-target events is directly related
to the level of AID expressed (Dorsett et al., 2007; Ramiro
et al., 2006; Ramiro et al., 2004). For example, Myc-Igh translo-
cations are rare events in B cells expressing physiological levels
of AID (1 in 33 107 cells) and increase in frequency to (1 in 2.53
104) in B cells overexpressing AID (Ramiro et al., 2006). It is
therefore essential that AID expression is tightly regulated
in vivo.
Under physiologic circumstances, AID expression is restricted
to activated B cells (Gonda et al., 2003; Sayegh et al., 2003), and
its concentration in the nucleus is limited by active export
(McBride et al., 2004). Furthermore, posttranslational modifica-
tion by phosphorylation at position S38 is required for interaction
between AID and replication protein A for optimal AID activity on
transcribed DNA (Basu et al., 2005; Chatterji et al., 2007;
McBride et al., 2006; Pasqualucci et al., 2006). The results pre-
sented here and in an accompanying paper in this issue of Immu-634 Immunity 28, 630–638, May 2008 ª2008 Elsevier Inc.nity (Teng et al., 2008) define an additional mechanism for regu-
lating AID expression in vivo. Aicda mRNA half-life is decreased
by a single miR-155 binding site within the 30 UTR. Our results
also highlight phenotypic differences between the miRNA bind-
ing-site mutation in Aicda and the deletion of miR-155. Both mu-
tations result in 2- to 3-fold-higher levels of Aicda mRNA and
protein in activated B cells. In contrast, Aicda155 is associated
with increased class-switch recombination, whereas mice with
a deficiency in miR-155 show an unexpected decrease in this
reaction (Thai et al., 2007). Nevertheless, both mutations result
in a substantial increase in Myc-Igh translocations. In the case
of miR-155-deficient B cells, translocation frequency is similar
to that found in ataxia-telangiectasia-mutated kinase (ATM)-
deficient B cells, which also display reduced amounts of class-
switch recombination (Ramiro et al., 2006; Reina-San-Martin
et al., 2004). The disproportionate increase inMyc-Igh transloca-
tions underlines the importance of AID regulation and suggests
that these events are not limited by the same factors that restrict
the degree of SHM and CSR.
Overexpression of Myc in B cells in transgenic mice results in
B cell lymphomas (Adams et al., 1985; Schmidt et al., 1988).
However, transgenic overexpression of AID does not (Muto
et al., 2006), and it is therefore not surprising that we have not
found lymphomas in Aicda155 or miR-155-deficient mice after
3 months and 1 yr of observation, respectively.
miRNAs regulate expression of large groups of genes by a
variety of mechanisms including cleavage, stability, cell-cycle
control, translation inhibition, and mRNA transport (Bartel,
2004; Filipowicz et al., 2008; Leung and Sharp, 2007; Meister
and Tuschl, 2004). It is therefore not surprising that they have
been implicated in malignant transformation (Esquela-Kerscher
and Slack, 2006; Hammond, 2007; Thomson et al., 2006). By
mutating the 30 UTR in Aicda, we have isolated the effects of
miR-155 on a single mRNA and determined that it destabilizes
the message, which in turn reduces the amount of AID protein
and the frequency of Myc-Igh translocations. Throughout evolu-
tion, miR-155 and its binding site in the 30 UTR of Aicda have
been conserved. Therefore, we speculate that the emergence
of miR-155 and AID in vertebrates and the conservation of their
interaction through evolution are related to minimizing chromo-
some translocations.
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miR-155 Suppresses AID-Mediated TranslocationsFigure 4. Igh to Myc Translocations in Stimulated B Cells from Aicda155 Mice
(A) Schematic representation of PCR assay forMyc-Igh translocations. Primers used to detect derivative chromosome 12 (derChr12) and derivative chromosome
15 (derChr15) translocations are represented as horizontal black and gray arrows, respectively. Internal oligonucleotide probes used in Southern-blot experi-
ments are shown as horizontal black bars.
(B) Myc-Igh translocations. B cells from Aicda155/ and Aicda+/ (Aicda/ mice not shown) were stimulated with LPS and IL4 for 4 days. Ethidium-bromide
agarose gels (EtBr, upper gels) and Southern blots of candidate translocations with Igh or Myc oligonucleotide probes collected from representative samples
(three independent spleens 6 3 107 cells per genotype) are shown.
(C) Total number of translocations obtained from Aicda155/ (p = 0.000139 versus Aicda+/), Aicda+/, and Aicda/ B cell. p value was determined with a
two-tailed Fisher’s exact test.
(D)Myc-Igh translocations. B cells from Aicda155/155 and Aicda+/+ were stimulated with LPS and IL4 for 4 days. Amplification products were separated on agarose
gels and stained with ethidium bromide (EtBr, upper gels). Southern blots of the EtBr stained gels were probed for Igh and Myc (three independent spleens,
100,000 cell per lane, 3.6 3 106 cells per genotype).
(E) Total number of translocations obtained from Aicda155/155 (p = 0.00879 versus Aicda+/+) and Aicda+/+ B cell. p value was determined with a two-tailed Fisher’s
exact test.
(F)Myc-Igh translocations assayed as in (B) except B cells were from miR-155-deficient and WT mice (five separate spleens assayed and representative samples
shown, 2 3 107 cells assayed per genotype).
(G) As in (C) except shows total number of translocations obtained from miR-155-deficient and WT mice. p = 0.0003 with a two-tailed Fisher’s exact test.miR-155 mutant mice showed higher levels of translocation
than Aicda155, indicating that miR-155 may target additional
mRNAs that cooperate to prevent Myc-Igh translocation. These
translocations are the key transforming events in Burkitt’s lym-
phoma (Klein and Dalla-Favera, 2008) and are known to be defi-
cient in miR-155 as a result of defects in processing of the gene
encoding miR-155 (Kluiver et al., 2006; Kluiver et al., 2007; Land-graf et al., 2007). Thus, our findings suggest a molecular rationale
for the development of human Burkitt’s lymphoma, in that ab-
sence of miR-155 predisposes activated B cells to Myc-Igh
translocations by increasing expression of AID and yet-to-be-
identified proteins that contribute to maintaining genomic integ-
rity (Di Noia and Neuberger, 2007; Kluiver et al., 2007; Kuppers
and Dalla-Favera, 2001).Immunity 28, 630–638, May 2008 ª2008 Elsevier Inc. 635
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Mice
Aicda nucleotides AGCATTAA, located in the Aicda 30 UTR, 468 bp down-
stream of the stop codon, were replaced with GCGCGCGC by gene targeting
(Figure S1A). The long arm of the targeting vector was 6.9 kb long and intro-
duced a LoxP site within the intron between Aicda exons 4 and 5 (Figure S2).
The short arm was a 1.5 kb fragment extending downstream of the 30 UTR. A
LoxP-flanked neomycin-resistance gene was used for positive selection, and
a diphtheria toxin gene was used for negative selection (Yagi et al., 1990). The
targeting construct was linearized and transfected into C57Bl/6 embryonic
stem cells (ESCs). ESC clones were screened and seven positive clones
were injected into C57Bl/6 blastocysts, and one produced chimeric mice
that transmitted the mutation. The genotype was confirmed by amplifying
the mutation with a primer external to the targeting construct and proximal
to the end of the short arm. The resulting amplification product was verified
by sequencing and digesting with AsceI, resulting in a digested wild-type allele
amplification product and nondigested Aicda155 product. The identity of
the resulting Aicda transcript was confirmed by reverse transcription of total
RNA from activated B cells followed by amplification of the Aicda transcript
from the 50 UTR to the 30 UTR at the end of the short arm and then by sequenc-
ing. To produce Aicda155/ mice, we crossed heterozygous Aicda155/+ mice
to Aicda/C57Bl/6 mice and used littermate Aicda+/ as controls. miR-155-
deficient mice were previously described (Thai et al., 2007). All mice were
maintained under specific pathogen-free conditions, and experiments were
performed under Rockefeller University IACUC approved protocols.
Lymphocyte Cultures and Translocation Assays
Resting B lymphocytes were isolated from the spleen with CD43 microbeads
(Miltenyi Biotech), cultured in RPMI supplemented with L-glutamine, sodium
pyruvate, 50 mM 2-Mercaptoethanol, and 10% FBS (GIBCO-BRL), and where
indicated cells were labeled with CFDA-SE (5 mM, Molecular Probes). The
B cells were stimulated with LPS (25 mg/ml) and IL-4 (5 ng/ml, Sigma) alone
or together with IL-5 (15 ng/ml, PharMingen) and BAFF (10 ng/ml, R&D sys-
tems) for production of plasmablasts (Horikawa and Takatsu, 2006). For the
plasma cell experiment, CD138+ B cells were sorted, and FACS was done
on day 5. Transloaction assays were exactly as previously described (Dorsett
et al., 2007; Ramiro et al., 2006). In brief, PCR of wild-type, Aicda/, miR-
155 deficient, Aicda155/, or Aicda155/155 was performed with total DNA pre-
pared from day 3 or 4 LPS + IL4 cultures. Data shown for Aicda155/ and
Aicda155/155 were from day 4 cultures without dead cell removal prior to DNA
preparation. Data for miR-155-deficient mice were from day 3 cultures with
dead cell removal prior to DNA preparation. Approximate cell number for
each sample was determined by DNA quantitation on an ethidium-bromide-
stained agarose gel (500 ng DNA = 100,000 cells). Subsequent amplification
of Myc to Igh switch-region translocations was done as previously described.
Amplification products were verified with Southern blots by probing for Myc
and Igh as previously described (Ramiro et al., 2004). Bands that probe for
both Myc and Igh represent Myc to Igh chromosomal translocations.
Flow Cytometry
Single-cell suspensions from bone marrow, spleen, or lymph node were incu-
bated with biotin-conjugated monoclonal antibodies anti-CD43, anti-IgM, anti-
B220, anti-CD95, anti-GL7, anti-CD19, anti-FAS, or anti-IgG1 and then stained
with streptavidin conjugated to FITC, PE, or APC (BD Biosciences). Germinal-
center cells were CD19+, Fas+, and GL-7+ cells sorted from lymph nodes 14
days after immunization. Data were collected with a FACSCalibur and ana-
lyzed with CellQuest and FloJo software. Cell sorting was on a FACSAria
and FACSVantage.
Immunizations and ELISA
Age- and sex-matched 8- to 12-week-old mice were immunized by footpad in-
jection with 50 mg of alum precipitated NP21-CGG (both from Biosearch Tech-
nologies). To measure serum-antibody amounts, we used goat anti-mouse Ig
(H+L) for capture and horseradish peroxidase (HRP)-conjugated goat anti-
mouse isotype-specific antibodies (Southern Biotechnology) for detection.
Values were calculated by comparison with mouse immunoglobulin standards
(Southern Biotechnology). Serial dilutions were performed for each sample,636 Immunity 28, 630–638, May 2008 ª2008 Elsevier Inc.and readings were taken within the linear range for each sample and adjusted
for dilution. Results reflect relative absorbance for each sample compared with
the standard control. All plates were developed with a Peroxidase Substrate
Kit (Bio-Rad), and absorbance was measured at 415 nm.
Immunoblotting
AID antibody was an affinity-purified polyclonal antibody against the carboxyl
terminus (EVDDLRDAFRMLGF) of AID and was previously described (McBride
et al., 2004). For immunoblot assays, cells were lysed in 20 mM Tris (pH 8.0),
200 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 1 mM DTT, 0.5 mM
EDTA, 1 mM PMSF, Protease inhibitor cocktail (Sigma). Fifty micrograms of
protein was immunoblotted with the AID antibody or tubulin antibody (abcam).
Band densities were quantified with ImageJ software, and relative AID amount
is a comparison of AID/tubulin ratios within each gel.
Quantitative PCR
Total RNA was isolated from sorted or LPS- and IL4-activated cells with TRIzol
reagent (Life Tecchnologies) according to the manufacturer’s instructions. The
first-strand cDNA synthesis was performed with 200 ng of total RNA primed
with random primers via the RT reaction protocol provided by the manufac-
turer (Invitrogen). qPCR was performed with Brilliant SYBR Green QPCR mas-
ter mix (Stratagene) containing 500 nM primers via standard amplification pro-
cedure. All samples were analyzed in triplicate and normalized to GAPDH
levels, and the result expressed as n-fold induction compared to wild-type
day 4 control. Primers forAicdawere forward 50-GAAAGTCACGCTGGAGACC
G-30 and reverse 50-TCTCATGCCGTCGCTTGG-30, and primers for GAPDH
were forward 50-TGAAGCAGGCATCTGAGGG-30 and reverse 50-CGAAGGTG
GAAGAGTGGGAG-30. To determine the half-life of Aicda155/ mRNA, we
treated B cells cultured with LPS + IL-4 for 72 hr when Actinomycin D was
added to the culture medium at 10 mg/ml final concentration for 0.5, 1, 1.5,
2, 3, or 4 hr. First-strand cDNA synthesis was performed with 200 ng of total
RNA primed with random primers (Invitrogen). Triplicate Aicda q-PCR were
preformed for each time point for each of two mice and normalized to GAPDH.
Calculation of Translocation p Values and Aicda RNA Half-Life
p value was calculated with a two-tailed Fisher’s exact test. Comparison be-
tween genotypes of the number of translocations per number of PCR reactions
was used to do the calculations. To determine theAicdaRNA half-life, we used
an exponential regression model of the data generated by Excel. That expo-
nential decay models the data correctly is supported by high R2 values (0.93
for Aicda155/ and 0.94 for Aicda+/) in the regression and the finding that
the log plot of the normalized data is linear. The half-life was determined
from the slope of the resulting lines.
Mutation Analysis
Genomic DNA from sorted CD19+Fas+GL7+ germinal-center cells of NP-KLH-
immunized mice was PCR amplified in 50 ml with PfuTurbo (Stratagene) for 30
cycles from 10,000–100,000 sorted cell equivalents in four independent reac-
tions that were pooled for cloning experiments. For 50 Sm, the primers and PCR
conditions have been described (Jolly et al., 1997; Reina-San-Martin et al.,
2003). The JH4 intron was amplified with 50-GGAATTCGCCTGACATCT
GAGGACTCTGC-30 and 50-CTGGACTTTCGGTTTGGTG-30 for 14 cycles at
94C (30 s), 55C (30 s), and 72C (90 s) and then with 50-GGTCAAGGAAC
CTCAGTCA-30 and 50-TCTCTAGACAGCAACTAC-30 for 21 cycles at 94C
(30 s), 55C (30 s), and 72C (30 s). Statistical significance was determined
by a two-tailed t test assuming unequal variance. Bcl6 primers were p369
50-CTTTCTTGGTTGGAGTCGAGG-30 and p370 50-CGGGCTTGAGGTCATTT
CTC-30, as previously described in (Muto et al., 2006). PCR reactions were per-
formed in triplicates, the products were pooled, and bands at the expected
size were gel extracted and cloned with TOPO-TA (Invitrogen). Bacterial colo-
nies were sequenced by Biotic Solutions and analyzed with CodonCode
Aligner software (CodonCode Coporation). Only good-quality sequence was
considered, as determined by inspection of the chromatograms.
SUPPLEMENTAL DATA
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630/DC1/.
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